Recently, new antithrombotic agents (anticoagulants and antiplatelet agents) have been developed. In Korea, insurance benefits (national health insurance drug prices) were set based on the results of large-scale clinical studies. The use of new anticoagulants (dabigatran; Pradaxa, rivaroxabn; Xarelto, apixaban; Eliquis) in patients with atrial fibrillation and new antiplatelet agents (prasugrel; Effient, ticagrelor; Brilinta) in patients with acute coronary syndrome are increasing rapidly. Although there are many large-scale clinical studies on the safety and efficacy of new anti thrombotic agents, the safety and efficacy studies in real-world patients with various comorbidities and basal characteristics are limited. In particular, most studies published until recently are the results of research on Westerners. In addition, studies of Asians whose side effects and pharmacological effects of antithrombotic agents are somewhat different from Westerners is very limited. Therefore, this study aims to analyze the current status of the use of new antithrombotic agents in Korea and to analyze the safety and effectiveness using the health insurance big data. 

The objective of this study is to compare and analyze the safety and effectiveness of new antithrombotic agents (anticoagulants and antiplatelet agents) in real-world setting.

1. To evaluate the safety and effectiveness of new antiplatelet agents  compared to clopidogrel in acute coronary syndromes.

2. To evaluate the safety and effectiveness of new anticoagulants compared with warfarin in atrial fibrillation.